These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 8090750)
1. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393 [TBL] [Abstract][Full Text] [Related]
3. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214 [TBL] [Abstract][Full Text] [Related]
4. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731 [TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740 [TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598 [TBL] [Abstract][Full Text] [Related]
7. Immune response during tumor therapy with antibody-superantigen fusion proteins. Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549 [TBL] [Abstract][Full Text] [Related]
9. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Dohlsten M; Sundstedt A; Björklund M; Hedlund G; Kalland T Int J Cancer; 1993 May; 54(3):482-8. PubMed ID: 8509223 [TBL] [Abstract][Full Text] [Related]
10. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649 [TBL] [Abstract][Full Text] [Related]
11. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Lando PA; Dohlsten M; Ohlsson L; Kalland T Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661 [TBL] [Abstract][Full Text] [Related]
13. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414 [TBL] [Abstract][Full Text] [Related]
14. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells. Gidlöf C; Dohlsten M; Kalland T; Tötterman TH Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852 [TBL] [Abstract][Full Text] [Related]
15. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477 [TBL] [Abstract][Full Text] [Related]
16. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR. Antonsson P; Wingren AG; Hansson J; Kalland T; Varga M; Dohlsten M J Immunol; 1997 May; 158(9):4245-51. PubMed ID: 9126986 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621 [TBL] [Abstract][Full Text] [Related]
18. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219 [TBL] [Abstract][Full Text] [Related]
19. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells. Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309 [TBL] [Abstract][Full Text] [Related]
20. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]